Vendor Intelligence Report: Henan Sahe Peptide

Executive summary

Henan Sahe Peptide is not a simple reject, but it is not a clean trust story either. Across 45 Finnrick lab tests, the headline record shows 36 pass / 8 fail, for an overall pass rate of 80%. The tested catalog is narrow and uneven: Tirzepatide is the more defensible sampled choice, while Retatrutide carries the heavier failure burden and needs lot-level verification. The methodology charts also show ratings compress under stricter fill and purity grading.

The OSINT record points to a functioning Chinese exporter with a short public storefront history and fragmented identity control. Registry snippets point to a Zhengzhou trading-company anchor, while the buyer-facing footprint moves across Sahe, Henan Sahe Polypeptide/Peptide, SH Peptide and a misspelled SH Petitde marketplace identity. That pattern can occur in export sales, but here it sits beside factory-direct claims that the public filings and office-suite address do not verify.

The strongest integrity concern is the SH Peptide storefront's reputation layer: Trustpilot-style score and review-count social proof displayed without a resolvable Trustpilot profile, followed by new before/after weight-loss Success Stories. The report also documents a supplier-forum post advertising anabolic steroids and raw powders alongside peptides, plus low-recourse payment rails and Hong Kong-forwarded logistics. Community reports include successful deliveries, so the sharper read is not no-ship; it is shipment through thinly documented channels where the exact COA-to-vial match matters.

For a buyer already considering Sahe, the report's practical use is product-specific: it separates acceptable sampled peptides from weaker ones, then tests whether the vendor's identities, payment recipient, COA trail and official domains line up before money or material changes hands.

Inside the full report:

• Per-product Finnrick pass/fail rates, methodology-divergence charts and Appendix A row-level data for Retatrutide, Tirzepatide and GHK-Cu
• Dated event timeline covering the 2019 registry snippets, 2025 domain launches, Anabolex supplier promotion and 2026 buyer threads
• Corporate identity map across Sahe, Henan Sahe Polypeptide/Peptide, SH Peptide and SH Petitde marketplace records
• Trustpilot verification captures, Success Stories screenshot and Gridinsoft/ScamAdviser reputation exhibits for shpeptide.com
• Payment, Hong Kong-forwarding and order-specific COA checks for buyers who proceed

Risk assessment

• Fabricated social-proof and testimonial risk — high: shpeptide.com displays Trustpilot-style TrustScore/review-count claims while Trustpilot shows no profile for shpeptide.com; the site also uses unverified weight-loss Success Stories.
• Controlled-substance and regulatory-exposure risk — high: Grace-Saha's Anabolex supplier post advertises anabolic steroids and raw powders alongside peptides.
• Corporate, manufacturer and channel-verification risk — medium: Henan Sahe/SH names are not tied by a complete registry filing; the strongest anchor is a Zhengzhou trading company, while public materials claim factory capability and provide no authoritative channel or anti-counterfeit list.
• Product-specific quality-control risk — medium: Retatrutide is the weaker current Sahe product at 79.66% with 24 tests, 19 pass / 5 fail; Tirzepatide and GHK-Cu score higher but still have recorded failures and require lot-specific COA checks.
• Payment-recipient and no-chargeback risk — medium: Crypto, Wise/bank-transfer-style payment, Hong Kong recipient questions and tracking friction reduce buyer recourse.